Avidity Biosciences initiates Phase 3 study for Del-desiran in Myotonic Dystrophy Type 1
Avidity Biosciences has launched Phase 3 open-label extension study for Del-desiran, focusing on long-term safety and efficacy.
Asset / Drug
Drug and asset intelligence for Avidity with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.